Human papillomavirus quadrivalent (types 6, 11, 16, 18 vaccine recombinant)

(Gardasil)

Human papillomavirus quadrivalent (types 6, 11, 16, 18 vaccine recombinant)

Drug updated on 8/24/2023

Dosage FormInjection (intramuscular; 0.5 mL)
Drug ClassVaccines
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in girls and women 9- through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, and 18 and the following diseases associated with the HPV types included in the vaccine: cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.
  • Indicated for the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grade 2 and grade 3, vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3, vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3, and cervical intraepithelial neoplasia (CIN) grade 1.
  • Indicated in boys and men 9 through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and the following diseases associated with the HPV types included in the vaccine: anal cancer caused by HPV types16 and 18, genital warts (condyloma acuminata) caused by HPV types 6 and 11, and anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 caused by HPV types 6, 11, 16, and 18.